PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Combination shows consistent benefit across prespecified post-progression outcomes
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Subscribe To Our Newsletter & Stay Updated
